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Objectives. Cognitive behavioural therapy (CBT) can improve symptoms of anxiety
and depression, but also reduces the risk of future relapse after therapy completion.
However, current CBT relapse prevention methods are resource-intensive and can be
limited in clinical practice. This paper investigates a personalized means of reducing
relapse using smart-messaging in two settings: research and routine care.
Design. Study 1 presents a cohort study comparing a cohort of smart-messaging users
versus non-users. Study 2 presents time series follow-up data from a case series of smart-
messaging users from clinical practice.
Methods. Fifteen of 56 CBT completers who participated in a trial for the treatment of
health anxietywrote advice theywouldwant if in future theyweredoingwell, experiencing
early warning signs of relapse, or experiencing full relapse. Following CBT, participants
received weekly text-message requests to rate their well-being. Dependent upon their
response, participants received tailored advice they had written, appropriate to the well-
being level reported after recovery fromhealth anxiety. Smart-messagingwas also trialled
in a routine practice sample of 14 CBT completers with anxiety and depression.
Results. Across a 12-month follow-up, participants receiving smart-messaging showed
greater health improvements than those who did not.Well-being scores showed stability
between CBT completion and 6-month follow-up among routine care patients.
Conclusions. These findings suggest that a low-intensity, personalized relapse
prevention method can have a clinical benefit following CBT for common mental health
problems.
Practitioner points
 Post-treatment outcomes may be improved using personalized smart-messaging to prevent relapse
following cognitive behavioural therapy (CBT) for health anxiety.
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 In clinical practice, post-treatment smart-messaging can bewell-used by patients andmay helpmaintain
stable well-being in the 6 months after CBT ends.
 This evidence supports the clinical utility of a brief tailored digital intervention, which can be integrated
within routine clinical practice with minimal therapist input.
 Overall, longer-term post-CBT outcomes may be improved by integrating a smart-messaging
intervention at the end of therapy.
Anxiety and depressive disorders are common in the general population and are often
recurrent with a chronic course (Kessler, Chiu, Demler, & Walters, 2005; Penninx et al.,
2011; Steel et al., 2014). Because of this, there are long-term implications for such
disorders including early retirement and comorbid chronic physical complaints (Hendriks
et al., 2015;Wittchen et al., 2011).Most peoplewith anxiety and depression experience a
lower level of functioning and residual symptoms of recurrence even if recovery is
achieved (Rhebergen et al., 2011). Effective treatments, such as antidepressant
medication, are available, but relapse rates remain high after discontinuation of treatment
(Scholten, Batelaan, Van Oppen, Smit, & Van Balkom, 2013). Cognitive behavioural
therapy (CBT) is effective in improving symptoms of anxiety and depressive disorders,
and post-treatment relapse rates can be lower than those achieved by antidepressant
medication alone (Cuijpers et al., 2013; Hollon et al., 2005).
The post-treatment relapse prevention attributes of CBT have been linked to the skills
learnt by patients attending CBT, because patients treated with CBT experienced more
change in thoughts and beliefs than those treated with antidepressants (DeRubeis et al.,
1990; DeRubeis, Siegle, & Hollon, 2008). Furthermore, CBT patients independently rated
as acquiring specific CBT skills and competencies through therapy were at lower risk of
relapse after treatment than those who did not, even after controlling for post-treatment
severity and change over treatment (Strunk, DeRubeis, Chiu, & Alvarez, 2007). These
studies suggest that acquisition of CBT-related coping skills is an important component of
relapse prevention. However, 30–50% of patients attending CBT for anxiety and
depressive disorders still relapse within the first year after treatment, with greater relapse
rates found in clinical practice than controlled research conditions (Delgadillo et al., 2018;
Hollon et al., 2005).
To address the substantial problem of relapse even after CBT for anxiety and
depressive disorders, a number of therapy enhancements have been developed to prevent
post-CBT relapse. These interventions have typically involved additional therapy sessions
focused on developing relapse prevention plans, identifying potential triggers for relapse,
and learning coping strategies to manage such eventualities (Bockting et al., 2005). Many
of these interventions are included in longer CBT treatment protocols, but CBT is often
shorter in clinical practicewith abbreviated relapsepreventionwork (Hansen, Lambert, &
Forman, 2002; NHS Digital, 2018). Attenuating relapse prevention activities may reduce
the long-term effectiveness of CBT interventions, with 53% of patients relapsing within
1 year from brief, low-intensity CBT-type interventions for anxiety and depression
(Delgadillo et al., 2018). This is considerably higher than relapse rates following CBT
including relapse prevention content (39%; Vittengl, Clark, Dunn, & Jarrett, 2007).
Overall, this suggests that relapse prevention interventions may have a benefit in helping
patients maintain improvements achieved in therapy.
However, CBT interventions to specifically prevent relapse are time- and resource-
intensive. Therefore, a number of alternative, digital means of reducing relapse have been
developed in recent years, which have several benefits. Digital health interventions may
help address the resource- and time-related barriers preventing routine use of
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interventions to reduce relapse in clinical practice, because of their low cost and ease of
access (Lingam & Scott, 2002; Paganini, Teigelkoetter, Buntrock, & Baumeister, 2018).
Digital health interventions (i.e., interventions delivered via desktop computers, tablets,
or mobile phones, often using Internet-based resources) can achieve similar effects to
high-intensity traditional approaches, but using much less therapist time (Hennemann,
Farnsteiner, & Sander, 2018). Digital health interventions have been used to increase the
reach and accessibility of relapse prevention interventions in several recent trials. Meta-
analyses of digital relapse prevention interventions suggest they can be effective for
anxiety and depressive disorders, but the benefits are moderated by the degree of
personalization included (Hennemann et al., 2018). Furthermore, minimal, but person-
alized, relapse prevention methods that include an individual plan are preferred if regular
contact with a mental health professional is not an option (Muntingh et al., 2019). This
suggests digital tools may present an effective and efficient means of reducing relapse in
anxiety and depressive disorders.
Conversely, there are identified weaknesses in digital health interventions. Specifi-
cally, low-intensity, automated interventions have historically had weaker effects than
high-intensity interventions delivered face to face (Rodgers et al., 2012). Furthermore,
few digital relapse prevention programmes are integrated with traditional one-to-one
CBT, despite this remaining the treatment medium most likely to be chosen by patients
(Berle et al., 2015). Therefore, current digital relapse prevention methods are often
unable to harness the knowledge and learning gained by patients during CBT that can be
key in preventing relapse (Strunk et al., 2007).
Current evidence suggests that brief, easily implemented reminders, such as targeted
text messages, can act as effective prompts for therapeutic and healthy behaviour change
(Boksmati, Butler-Henderson, Anderson, & Sahama, 2016; Hall, Cole-Lewis, & Bernhardt,
2015; Robotham, Satkunanathan, Reynolds, Stahl, & Wykes, 2016). ‘Smart-messaging’
interventions like this can improve physical and mental health across a range of health
problems (Rathbone & Prescott, 2017). Yet, smart-messaging has not been used, in a
personalized way, to enhance relapse prevention in CBT for anxiety and depressive
disorders, despite evidence that smart-messaging is one of the easiest and most cost-
effective digital interventions to integrate within routine care (Boksmati et al., 2016; Hall
et al., 2015; Wong et al., 2016). Using personalized smart-messaging prepared by the
therapist and patient before CBT ends may help to draw on the strengths of digital health
interventions and overcome the difficulties associated with low-intensity interventions.
This study evaluates initial evidence of effectiveness and feasibility for a personalized,
minimal contact, post-CBT digital intervention that is integrated with key learning from
therapy. It applies well-used smart-messaging technology (The King’s Fund, 2018) to
regularly deliver personalized relapse prevention messages written by the individual
patient and tailored to the patient’s current mood state. This intervention addresses a key
research gap, as no studies have investigated integrated, minimal contact, personalized
smart-messaging interventions for relapse prevention post-CBT in anxiety and depressive
disorders (Hennemann et al., 2018).
This paper is separated into two observational studies to evaluate the feasibility and
clinical effectiveness of smart-messaging as a post-CBT relapse prevention tool: Study 1
compares long-term clinical outcomes of smart-messaging relapse prevention users with
non-users from a clinical trial sample of patients with health anxiety and multiple
comorbidities. Study 2 assesses the feasibility of smart-messaging use in routine clinical
practicewith cancer patients experiencing comorbidmental health problems. Each study
is described in turn, and a joint discussion is presented at the end.
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Overall, given the recent rise in stand-alone digital health interventions, this paper
presents proof-of-concept evidence for a digital health interventionwhich emphasizes the
personalized approaches associated with greater outcome improvement. The interven-
tion also closely integrates with one-to-one CBT processes, which remains the dominant
means of CBT provision.
STUDY 1: CLINICAL OUTCOMES OF SMART-MESSAGING USERS




An exploratory observational design was applied to data from a randomized controlled
trial of remotely delivered CBT for health anxiety versus usual care among high service
utilizers (Morriss et al., 2019). The 791 participants randomized to CBTwere offered 5–15
sessions delivered via either videoconferencing (n = 54) or the telephone (n = 14); 11
did not attend any sessions. The current study’s objective was to compare clinical
outcomes from participants who completed treatment and used post-treatment smart-
messaging with treatment completers who did not use post-treatment messaging.
Participants
Participants were recruited from primary and secondary care after being approached by
their treating clinician. If participants scored ≥18 on the 14-item Short Health Anxiety
Inventory (SHAI) and attended two or more urgent care appointments in the previous
12 months, they were eligible for inclusion. Participants were excluded if they were at
immediate risk of harm to themselves or others and had moderate-to-severe intellectual
disability or severe mental or physical illness to the extent that engagement in the
intervention would not be possible (e.g., communication difficulties). Fifty-four patients
were excluded from the source trial due to not meeting eligibility criteria.
Fifty-three of the 79 participants were classified as ‘completers’ (attended at least five
sessions), which is deemed an adequate treatment dose for clinical effect inCBT for health
anxiety (Tyrer et al., 2014). Fifteen CBT completers opted to trial post-treatment smart-
messaging (smart-messaging group), and 38 did not (no-messaging group). Smart-
messaging participants attended a mean of 11.9 (SD = 2.4) sessions, and no-messaging
participants attended 11.1 (SD = 3.0). At 6 months, 100% follow-up was achieved for
smart-messaging users and 84% for non-users. At 12-month follow-up, 93% follow-up was
achieved for smart-message users and 68% for non-users.
Interventions
CBT for health anxiety
An established CBT for health anxiety treatment protocolwas adapted for remote delivery
through collaboration between two patient advisors and a CBT therapist (Patel et al.,
2016; Tyrer et al., 2014; Tyrer et al., 2011). Treatment included identification of key
1 There were 78 participants randomized to CBT, and one participant was randomized to usual care but offered CBT in error.
Their data are included in the analysis. Therefore, the total sample is 79.
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beliefs and assumptions about health and illness, followed by testing and evaluation of
beliefs using behavioural experiments. Potentially problematic anxiety-maintaining
cognitive and behavioural strategies, such as repeated reassurance-seeking or body
checking, were collaboratively identified and reduced or stopped.
Post-treatment smart-messaging
Anestablished smart-messaging systemwasused to develop thepost-treatmentmessaging
intervention (http://www.simple.uk.net/). Their smart-messaging system is employed
across several different health services to help people manage their health long term (The
King’s Fund, 2018).
In the final two CBT sessions, a relapse prevention plan was developed. Participants
were asked if they wished to have elements of their relapse prevention plan sent to them
in text messages after CBT sessions had finished. Those who gave written consent to this
were then led through the following process: Using template worksheets (see Supporting
information), participants and therapists firstly identified characteristic patterns of
responding for the individual patientwhen: (1) doingwell, (2) experiencing earlywarning
signs of relapse, and (3) experiencing full relapse. These included patterns of thought,
behaviour, and characteristic emotional responses. Secondly, the participantwas asked to
imagine themselves in 3–6 months’ time: (1) doing well, (2) experiencing early warning
signs of relapse, and (3) experiencing full relapse. The participant was then asked what
advice or actions they would suggest if they were able to send themselves a text message
under each of these three circumstances. The patient and therapist then collaboratively
developed a series of brief advice messages for each of the three levels using the learning
gained from CBT sessions (see Table 1 for example messages for each level). Finally,
participants were asked if they were able to come up with a slogan or headline
summarizingwhat they had learnt from therapy that they feltwould help them staywell in
future. Therapists encouraged patients to make these slogans as personally relevant as
possible, rather than general statements. For example, one participant wrote themessage
‘Uncompleted projects are not necessarily failures’ as a summary of key learning from
therapy. This is not necessarily a key issue for people with health anxiety in general, but
for the participant in question this was a focus of therapeutic work; much anxiety had
revolved around self-criticism for not finishing projects. Participants were encouraged to
write three or more summary headlines (Table 2 gives example headline summaries
written by participants).
For each of the 25 weeks after CBT sessions had finished, participants received a text
message asking them to rate their well-being that week from 0 to 5 in a responding text,
where 0was theworst possiblewell-being and5was the best. If the participant responded
with 5 or 4, they received a text message containing some of the advice they had written
and wanted to receive if doing well. If participants responded with 3 or 2, they received
some of their own advice for if they were experiencing early warning signs of relapse. If
the participant responded with 1 or 0, they received their own advice for managing full
relapse. At a different point each week, participants also received a message containing
one of their summary slogans.
Outcome measures
Outcomes were collected by independent researchers, blind to treatment group
allocation at baseline, 3-, 6-, 9-, and 12-month follow-up. Given the high rates of
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comorbidity among health anxiety sufferers, a range of physical and mental health
outcomes was used to assess therapeutic change:
 The 14-item Short Health Anxiety Inventory (SHAI) is a measure of health anxiety
assessing worries about health and bodily changes. The SHAI shows excellent test–
retest reliability (r = .90) and convergent validity with assessment of hypochondriasis
(r = .85) (Salkovskis, Rimes, Warwick, & Clark, 2002).
 The seven-itemGeneralised Anxiety Disorder (GAD-7) Scale is ameasure of generalized
anxiety symptoms based on diagnostic criteria with excellent test–retest reliability
(ICC = .83) and good convergent validitywith other anxiety measures (rs = .72 to .74)
(Spitzer, Kroenke, & Williams, 2006).
 The nine-item Patient Health Questionnaire (PHQ-9) measures depression symptoms
based on diagnostic criteria for major depression. Excellent test–retest reliability has
been demonstrated (a = .84) and good convergent validity with general mental health
assessment (r = .73) (Kroenke, Spitzer, & Williams, 2001).
 The EuroQol – 5Dimensions – 5 Levels (EQ-5D-5L,Herdman et al., 2011) is ameasure of
quality of life assessing functional, physical, and mental health components of life
quality. It has shown acceptable test–retest reliability (ICC = .52) and good convergent
validitywith established assessments ofwell-being (rs = .77) (Janssen, Birnie,Haagsma,
& Bonsel, 2008; Janssen et al., 2013).
 The visual analogue scale (VAS, Herdman et al., 2011) assesses general health, as part of
the EQ-5D, and shows similar psychometric properties.
Table 1. Example relapse prevention messages
Relapse stage Personal experience Personal advice message
Doing well Enjoy planning my days [ ] look forward
to events, meets with friends etc.
Be proud of yourself for the things you
are achieving and doing. [P 03014]
Going to the gym, playing football and
with kids. Getting on well with family
and friends. In the moment, enjoying
life
You’ve got a good plan in place – stick to





problems. Probably start looking up
symptoms on the [inter]net which in
turn will make my anxiety worse
Try to remember that looking on the
[inter]net can give false information
and may sensationalise symptoms.
Learn by your mistakes. Try and avoid
constantly asking for reassurance. [P
01046]
Feeling less able to control my worrying
and may start to effect work, start
making excuses not to see
friends/family, not exercis[ing] as much
Try and do things that you enjoy doing,
like going running even if you don’t feel
like it. Be the yoga me! [P 03009]
Full relapse I start thinking that my friends actually
don’t like me and that everyone
criticises me behind my back.
Overthink
Your friends like you, otherwise they
would not hang out with you. You are
loved [P 01104]
Pacing about, needing reassurance,
feeling panicky, tingling in hands and
feet, [want] to see [the family doctor]
This is anxiety bullying you, there is
nothing else wrong. Tell your anxiety
bully where to go. [P 06005]
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 The 15-item Patient Health Questionnaire (PHQ-15) is a measure of somatic symptoms,
wherein psychological distress is manifested in physical symptoms. Acceptable test-
retest reliability has been achieved (r = .56) (Kroenke, Spitzer, & Williams, 2002).
 The Work and Social Adjustment Scale (WSAS; Mundt, Marks, Shear, & Greist, 2002)
assesses functional impairment and has shown good-to-excellent test–retest reliability
(a = .73) and moderate-to-strong correlation with clinician interview (a = .81 to .86)
and depressive symptomatology (a = .76). The focal problems identified for assess-
ment on theWSASwere described as symptoms or pain (e.g., Because ofmy symptoms/
pain, my ability to work is impaired).
Procedure
If potential participants consented to contact, independent researchers then carried out a
telephone screening for health anxiety severity and service use. Researchers conducted
follow-up assessments by telephone, videoconference, in person, or by email depending
on participant preference (See Morriss et al, 2019 for more details).
Method of analysis
The clinical and demographic characteristics of CBT completers who received smart-
messaging were compared to those who did not. Mann–Whitney U and chi-squared tests
were used to compare characteristics for continuous and categorical variables, respec-
tively.
The outcomes in the smart-messaging and no-messaging groups were compared using
multilevel modelling, given the repeated measurement design. A significant 62–78% of
outcome covariance was explained by clustering within participants over follow-up
assessment time. This suggested that multilevel modelling was an appropriate analytic
method to account for both within- and between-participant variance over time. A two-
level hierarchical data structure was applied, nesting ordered assessment time points
(‘time’ hereafter – level 1) within associated participants (level 2). This method also
offered more accurate estimates of change over the 12-month follow-up period, whereas
more typical multiple linear regression analyses usually rely on a single assessment time
Table 2. Headline summary message examples
Age range Gender Personal headline reminder message
50–60 Female The fear will pass. I can cope, I have coped [P 01071]
20–30 Male Generally anxieties come and go, often they resolve on their own. [P 01084]
40–50 Female Keep in touch with family and friends [ ]. They won’t think any less of you even
if you don’t feel 100% and seeing people makes you feel better. [P 01024]
20–30 Female You are not your thoughts and they do not control or define you! [P 01108]
20–30 Female Do things for fun, even in stressful times, plan in leisure time (cooking, sewing)
[P 01096]
30–40 Female [Try] not to look to Google or check my body for answers – it doesn’t help!
[P 02007]
60–70 Male Try to continue as if the anxiety were not there and act as you would usually.
Don’t let the anxiety interrupt your plans! [P 02006]
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point and are more affected by missing data. Applying conventional model building
guidelines, each parameter was added to the model individually and the goodness of fit
was assessed using 2 log likelihood (Raudenbush & Bryk, 2002). Parameter estimation
was made using maximum likelihood. Fully adjusted models included random intercepts
and fixed slopes with level 2 predictor variables: time (adjusting for ordered assessment
time point); baseline outcome score (adjusted for initial clinical severity); and smart-
messaging (the target predictor comparing smart-messaging versus no-messaging).
Analysis was conducted using SPSS 24.
Ethical approval was obtained from the National Research Ethics Service, London-
Riverside Committee (reference 14/LO/1102).
Results
There were no significant differences identified between the smart-messaging and no-
messaging groups on any observed baseline clinical or demographic characteristics
(Table 3). There were also no significant differences between smart-messaging users and
non-users at 3-month follow-up on any outcome (all Z < 1.75, p > .080).
Table 3. Participant characteristics
Post-treatment
messagingn = 15 No messagingn = 38
Demographics
Females 12 (80%) 30 (79%)
Mean age (SD) 39 (15) 37 (17)
Ethnicity
White British 10 (67%) 29 (76%)
Others 5 (33%) 9 (24%)
Employed 6 (40%) 12 (32%)
Clinical characteristics
Baseline SHAI (SD) 26.7 (4.8) 27.0 (5.2)
Baseline PHQ-9 (SD) 13.2 (6.6) 13.2 (6.5)
Baseline GAD-7 (SD) 13.7 (5.7) 12.5 (5.9)
Baseline PHQ-15 (SD) 11.7 (5.9) 15.0 (4.8)
Baseline WSAS (SD) 18.9 (11.3) 20.5 (11.5)
Baseline EQ-5D-5L Utility Index (SD) 0.609 (.229) 0.627 (.268)
Baseline VAS (SD) 54.3 (22.4) 54.0 (20.4)
Mean number of SCID Diagnoses (Range) 6 (0-14) 7 (1-16)
Generalized anxiety disorder 12 (80%) 24 (63%)
Hypochondriasis 9 (60%) 22 (58%)
Somatoform disorder 8 (53%) 25 (66%)
Current depressive episode 8 (53%) 26 (68%)
Panic disorder 10 (67%) 23 (61%)
Mean chronic physical health problems 1 (0–6) 1 (0–4)
Median sessions attended (IQR) 12 (4) 12 (4)
Note. Abbreviations: EQ-5D-5L, EuroQol – 5 -Dimensions – 5 -Levels; GAD-7, Generalised Anxiety
Disorder – 7 -items; IQR, interquartile range; PHQ-15, Patient HealthQuestionnaire – 15 -items; PHQ-9,
Patient Health Questionnaire – 9 -items; SCID, Structured Clinical Interview for the Diagnostic and
Statistical Manual of Mental Disorders IV; SD, standard deviation; SHAI, Short form Health Anxiety
Inventory; VAS, visual analogue scale; WSAS, Work and Social Adjustment Scale.
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Smart-messaging users responded to an average 13 messages (54%; SD = 5.7;
range 2-24) of the 24 response opportunities. There were trends for greater
outcome improvements among smart-message users compared to non-users on all
measures across 12-month follow-up when controlling for baseline differences in
severity and change over time (Figure 1). Differences were significant for overall
health (VAS; B2 = 13.14, SE B = 4.40, p = .004), generalized anxiety (GAD-7;
B = 3.04, SE B = 1.18, p = .014), depression (PHQ-9; B = 3.03, SE B = 1.35,
p = .029), and quality of life (EQ-5D-5L; B = .135, SE B = .048, p = .008); but non-
significant for work and social adjustment (WSAS; B = 3.35, SE B = 2.21,
p = .137), somatic symptoms (PHQ-15; B = 1.33, SE B = 1.20, p = .273), and
health anxiety (SHAI; B = 0.63, SE B = 1.75, p = .721). Visual inspection of mean
outcome trends over time indicates that differences between smart-message users
and non-users grew over the 12-month follow-up (see Supporting information for
outcome trends between groups over time). The greater improvements reported by































Figure 1. Percentage greater outcome improvement of post-CBT smart-messaging users versus non-
users. Note. EQ-5D-5L, EuroQol – 5 Dimensions – 5 Levels; GAD-7, Generalised Anxiety Disorder – 7
items; PHQ-15, PatientHealthQuestionnaire – 15 items; PHQ-9, PatientHealthQuestionnaire – 9 items;
SHAI, Short Health Anxiety Inventory; VAS, visual analogue scale; WSAS, Work and Social Adjustment
Scale. **p <. 01; *p < .05.
2 All beta values reported are non-standardized.
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non-users in quality of life (EQ-5D, 0.135), general health (VAS, 13.14), and
generalized anxiety (GAD-7, 3.04) (Pickard, Neary, & Cella, 2007; Walters & Brazier,
2005; Zahra et al., 2014). Furthermore, a greater proportion of smart-message users
achieved minimal clinically significant improvement at 12-month follow-up than non-
users in general health (79 vs. 42%), generalized anxiety (79 vs. 56%), depression
(57 vs. 40%), quality of life (35 vs. 25%), and health anxiety (92 vs. 81%) with
similar proportions of clinically important change in somatic symptoms (21 vs.
19%).3
Discussion
This study offers initial evidence that post-treatment smart-messagingmay support greater
outcome improvement over a 12-month follow-up period. Themethods used suggest that
participants receiving smart-messaging may have better retained or continued to develop
learning from CBT sessions several months after treatment ended. Engagement data
indicate that participants responded to themajority of smart-messageprompts, suggesting
there was active uptake of the intervention among users that may have contributed to
observed differences.
The study must still be seen as initial evidence, given the small sample of participants
whoopted touse smart-messaging. The lowuptake also suggested that the acceptability of
the intervention requires further investigation. Low uptake is common problem in digital
health interventions (e.g., Gilbody et al., 2015), partly due to the self-directed uptake and
engagement required. Therefore, the self-selecting sample is an important limitation given
that therewas no control for patient self-motivation factors. The lack of a standardized and
clear means of presenting the smart-messaging intervention may have contributed to
inconsistent patient uptake: Information provision was variable, and some patients
received limited understanding of the intervention’s potential for benefit. This may help
explain the low uptake and suggests a clear standardized rationale be used in future
research. Nonetheless, there were no identified differences between groups in clinical or
demographic characteristics suggesting a relatively comparable sample. Furthermore,
baseline severity and change over timewas controlled in themain analysis to support a fair
comparison between groups. However, the possibility remains that the self-selecting
sample of smart-messaging users may differ from the remaining sample on some
unassessed, but significant characteristic, such as motivation or differences in effects
between therapists. Systematic data were not collected on the reasons for refusal among
non-users of the intervention. This would help clarify means of addressing engagement.
Despite consistent trends for greater improvement among smart-message users on all
outcomes, there was no significant difference between groups on the primary treatment
target: health anxiety. If smart-messaging was indeed enhancing therapeutic effects, this
finding suggests that it lacked specificity, as the CBT interventionwas particularly focused
on improving health anxiety.
Overall, this study indicates that the use of smart-messaging to improve relapse
prevention is worthy of formal evaluation in a randomized controlled trial, due to its
potential as a cheap and accessible means of enhancing CBT outcomes. Study 2 presents
initial evidence from the application of smart-messaging in routine clinical practice.
3No agreed minimal clinically important difference is currently available for the WSAS.
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This study presents a feasibility clinical case series of participants who received CBT in a
clinical psychology service for cancer participants experiencing anxiety and/or depres-
sion. Participants completing treatment were offered post-treatment smart-messaging,
and their well-being was tracked over the 25-week smart-messaging follow-up period
using the well-being scores that they texted in responses. The trends of well-being were
then assessed for stability and consistency.
Participants
Fourteen participants4 were referred by cancer care staff to a clinical psychology service
and completed CBT offered by one of four therapists. Participants attended amean of 12.4
sessions (SD = 5.0); they had a mean age of 53 (SD = 13.6), with primary cancers from
five different sites (5 breast, 4 lower gastrointestinal, 1 haematology, 1 brain, and 1 head
and neck). Four participants were receiving palliative care for metastatic cancer, and the
remainder received curative treatment. All participants consented to the use of smart-
messaging, as previously described, and anonymous use of text data. The results of Study 1
were used to explain the method and potential benefits of smart-messaging to patients
recruited in Study 2.
Interventions
CBT
The clinical psychology service offered participants CBT interventions with the aim of
addressing problematic responses to cancer diagnosis and treatment rather than aiming to
change symptoms of cancer themselves. For example, several participants included in the
case series were highly anxious about cancer recurrence after treatment was complete,
but reactions such as repeated body checking and reassurance-seeking only served to
maintain anxiety (Salkovskis, Warwick, & Deale, 2003). Unhelpful cognitive or
behavioural reactions were identified and collaboratively reduced or stopped in a similar
manner to CBT in the above-described trial.
Smart-messaging
The same set-up and running procedures for smart-messaging were used as in the above-
described trial.
Procedure
Participant ratings of well-being texted in response to smart-messaging each week (0–5;
where 0 is the worst and 5 is the best) were collated by the clinical psychology service
during the 25-week smart-messaging follow-up period. An identification key was used to
4 Two patients using smart-messaging in the case series were not diagnosed with cancer, but did experience anxiety and
depression at baseline, so remain included.
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link the anonymous unique identifier used by the smart-messaging software with the
participating participant.
Outcome measures
Well-being (0-5) scores were used as a proxy outcome measure, and the stability of well-
being scores was used as an assessment of relapse. Therefore, where there was no
significant change in well-being score across follow-up time, the gains achieved from
therapy were deemed to be retained and relapse prevented. However, if there was a
significant deterioration in well-being score trends, it was considered a relapse.
Method of analysis
Simulation modelling analysis (SMA; Borckardt et al., 2008) was applied to give an
individual-level assessment of stability in weekly well-being scores over the 25-week
smart-messaging follow-up period. SMA allows for examination of individual time series in
terms of change over repeated-assessment time points and their statistical significance
using bootstrappingmethods that account for the length and autocorrelation of observed
data streams. This approach generates fewer Type I and Type II errors than visual data
inspection (Borckardt et al., 2008). Applied towell-being scores over time, SMAcomputes
a correlation (Pearson r) between the observed data and a linear slope vector for time:
Such that negative coefficients indicate deterioration over time, positive coefficients
indicate improvement, and zero coefficients indicate stability (no change). SMA then
simulates 1,000 data streams, with the same autocorrelation and n as the observed data,
drawn randomly from a null distribution of data streams. Finally, SMA produces a p value
for the observed coefficient: representing the empirical probability of observing a
coefficient of equal or greater magnitude in a null distribution of data streams (with
matched properties, in terms of n and autocorrelation). Thus, non-significant values
indicate that an individual’s scores are stable over the follow-up period. The purpose-
made SMA software was used to complete the analysis (available at http://www.clinica
lresearcher.org/).
Overall stability in well-being across cases over the smart-messaging follow-up period
was assessed using Wilcoxon signed ranks test of (group level) difference between the
first week well-being score and the last recorded well-being score (average week at 23).
Ethical approval was not required as Study 2 evaluated routinely collected data from
clinical practice, but the evaluation was registered with the participating health care
organization.
Results
Of the 14 cases assessed, 11 (79%) showed individual stability in well-being scores and 3
(21%) showed deteriorating trends over the 6 months following CBT completion
(Figure 2). Participants responded to the 25 message requests for well-being scores an
average of 17 times, giving a mean response rate of 68% (SD = 6; Range = 7–25).
At the group level, the first and last recorded well-being scores had identical means
(3.3, SD = 1.1). Given that last recorded well-being scores were received on average at
week 23, this suggests overall stability of well-being in the 6 months after CBT was
completed (Z = .07, p = .942).
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Discussion
This study suggests there is a high rate of stability in well-being ratings reported in the
6 months following CBT by users of personalized smart-messaging. Furthermore, there is
a high rate of engagement with the smart-messaging intervention, with participants
responding to smart-message requests on the majority of occasions.
If the use of idiosyncratic well-being ratings is accepted as a proxy assessment of
outcome stability, rates of relapse in this study compare favourably with other studies of
CBT follow-up in routine care without smart-messaging (Delgadillo et al., 2018).
However, this study cannot offer a direct comparison with participants who did not use
smart-messaging and it is unclear whether 0–5 well-being scores offer a meaningful
assessment of outcome stability. Future research could include concurrent standardized
symptom assessments alongside the 0-to-5 well-being scale to assess its reliability and
concurrent validity. If the method used is found to have adequate sensitivity, reliability,
and validity, it could offer a simple and effective means of follow-up outcome assessment.
In summary, this study suggests that smart-messaging may be a feasible and engaging
tool for users after CBT completion in routine care.
GENERAL DISCUSSION
This paper offers evidence that using personalized smart-messaging, tailored to patients’
emotional state, may reduce relapse after CBT. Study 1 suggests that smart-messagingmay
contribute to greater improvement in a range of clinical outcomes. Study 2 indicates
feasibility of smart-messaging in routine care, due to a high level of patient engagement
with the intervention in routine care and potential use of smart-messaging to track post-
treatment progress in clinical practice.
The studies reported support existing evidence that smart-messaging, through a brief





















Follow-up assessment point (weeks)
Figure 2. Average weekly well-being score over 6-month follow-up.
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health (Rathbone & Prescott, 2017). This paper also supports current evidence on the
effectiveness of digitalmethods for relapse prevention in anxiety and depressive disorders
(Hennemann et al., 2018). This paper adds to the literature by providing evidence that
digital relapse prevention methods can be fully integrated with traditional, therapist-
facilitated CBT (even if delivered over videoconferencing). This paper also extends
evidence for smart-messaging by showing the potential benefits of personalizing the
messages patients received in linewith key therapeutic learning. Current CBT theorymay
support a mechanistic explanation of the results reported: The learning of key CBT
competencies enhances post-treatment prognosis (Strunk et al., 2007); it is possible that
smart-messaging enhances and potentially continues this learning beyond the end of
therapy sessions.
Existing digital health interventions have indicated the potential to increase reach and
accessibility of relapse prevention alongside improvements in cost-effectiveness. This
study suggests that integration of smart-messaging can add greater long-term benefits to
relatively brief CBTwith no additional therapist time required. Therefore, this study offers
initial indications for an intervention that can be spread easily and may save clinical
resources alongside potential for improved patient benefit.
The use of multiple independently collected physical health, mental health, and
functional outcomes over a 12-month follow-up period meant that outcomes could be
compared in a number of domains. Within this design, the consistently superior
performance among smart-messaging users gave a persuasive case for the potential value
of the intervention. The illustration of smart-messaging’s use in routine practice helped
demonstrate the pragmatic feasibility of the intervention through data on usage and
stability of well-being.
However, this paper remains a proof-of-concept study requiring more rigorous
assessment in future research, given the limitations associated with the use of a self-
selecting sample in Study 1 and the lack of a comparator group or validated outcomes in
Study 2. Longer follow-up periods would also help to give a clearer indication of any
relapse prevention benefits offered by smart-messaging. Although relapse often occurs
within the first year after CBT, 2-year follow-up gives a better indication of long-term
prognosis (e.g., Kuyken et al., 2008). The addition of a systematic evidence-based
rationale for the use of smart-messaging in Study 2, which was missing from Study 1, may
explain the lowuptake observed. This could help improve engagement in future research.
In future research, smart-messaging should be formally evaluated in a randomized
controlled trialwith a longpost-CBT follow-upperiod. Future research could also evaluate
whether personalization of messages has an added benefit over a standardized post-
treatmentmessaging protocol. This type of researchwouldmore clearly give evidence for
the feasibility and acceptability of the intervention, which remains unclear given the low
uptake in Study 1. Therefore, further testing may be required prior to a full trial. Future
testing of post-intervention smart-messaging interventions would be strengthened by
expanding the scope to examine its utility with different disorders, interventions, and
patient populations. The mechanisms for any change associated with smart-messaging
should also be investigated in future research. Established methods of assessing CBT
competencies could be used to assess whether these competencies are maintained or
enhanced by smart-messaging.
In summary, patients who receive CBT for anxiety or depressive disorders may benefit
from personalized post-treatment smart-messaging. However, larger-scale randomized
evaluation is required before a dependable assessment of its value can be reached.
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Supporting Information
The following supporting informationmay be found in the online edition of the article:
Figure S1. Change in general health (VAS) over time between smart-messaging users
and non-users (higher scores indicate greater health improvement).
Figure S2. Change in generalized anxiety (GAD-7) over time between smart-
messagingusers andnon-users (lower scores indicate greater symptom improvement).
Figure S3. Change in depression (PHQ-9) over time between smart-messaging users
and non-users (lower scores indicate greater symptom improvement).
Figure S4. Change in quality of life (EQ-5D-5L) over time between smart-messaging
users and non-users (higher scores indicate greater quality of life improvement).
Figure S5. Change in work and social impairment (WSAS) over time between smart-
messaging users and non-users (lower scores indicate greater functional improve-
ment).
Figure S6. Change in somatic symptoms (PHQ-15) over time between smart-
messagingusers andnon-users (lower scores indicate greater symptom improvement).
Figure S7. Change in health anxiety (SHAI) over time between smart-messaging users
and non-users (lower scores indicate greater symptom improvement).
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